Seeking Alpha

Abbott Labs (ABT) and Neurocrine Biosciences (NBIX) are starting a 24-week Phase III trial of...

Abbott Labs (ABT) and Neurocrine Biosciences (NBIX) are starting a 24-week Phase III trial of elagolix, a treatment for endometriosis, which is a debilitating gynecological disease that affects around 100M women worldwide and can cause infertility. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector